Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.author||Siok Shen Ng||en_US|
|dc.contributor.author||Nai Ming Lai||en_US|
|dc.contributor.author||Nowrozy Kamar Jahan||en_US|
|dc.contributor.other||Taylor's University Malaysia||en_US|
|dc.contributor.other||University of Utah||en_US|
|dc.contributor.other||Monash University Malaysia||en_US|
|dc.contributor.other||University of Bristol, Faculty of Medicine and Dentistry||en_US|
|dc.identifier.citation||Scientific Reports. Vol.10, No.1 (2020)||en_US|
|dc.description.abstract||© 2020, The Author(s). Warfarin care bundles (e.g. genotype-guided warfarin dosing, patient’s self-testing [PST] or patient’s self-management [PSM] and left atrial appendage closure) are based on the concept of combining several interventions to improve anticoagulation care. NOACs are also introduced for stroke prevention in atrial fibrillation (SPAF). However, these interventions have not been compared in head-to-head trials yet. We did a network meta-analysis based on a systematic review of randomized controlled trials comparing anticoagulant interventions for SPAF. Studies comparing these interventions in adults, whether administered alone or as care bundles were included in the analyses. The primary efficacy outcome was stroke and the primary safety outcome was major bleeding. Thirty-seven studies, involving 100,142 patients were assessed. Compared to usual care, PSM significantly reduced the risk of stroke (risk ratio [RR] 0.24, 95% CI 0.08–0.68). For major bleeding, edoxaban 60 mg (0.80, 0.71–0.90), edoxaban 30 mg (0.48, 0.42–0.56), and dabigatran 110 mg (0.81, 0.71–0.94) significantly reduced the risk of major bleeding compared with usual warfarin care. Cluster rank plot incorporating stroke and major bleeding outcomes indicates that some warfarin care bundles perform as well as NOACs. Both interventions are therefore viable options to be considered for SPAF. Additional studies including head-to-head trials and cost-effectiveness evaluation are still warranted.||en_US|
|dc.title||Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis||en_US|
|Appears in Collections:||Scopus 2020|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.